Search research articles
Contact Us
Filters
Showing results (81-90 of 451) with videos related to
Page
of 46
Sort By:
Asian Journal of Andrology
|
April 24, 2012
Helping to address the over treatment of prostate cancer: tools to differentiate lethal and non-lethal phenotype in prostate cancer
Robert H Getzenberg, H Ballentine Carter
Urology
|
December 23, 2014
Reply: To PMID 25440986
Katarzyna J Macura, H Ballentine Carter
Integrative Organismal Biology (Oxford, England)
|
June 17, 2024
The Meioflume: A New System for Observing the Interstitial Behavior of Meiofauna
W M Ballentine, K M Dorgan
The Journal of Urology
|
November 7, 2006
The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate
Danil V Makarov, H Ballentine Carter
Health Affairs (Project Hope)
|
December 5, 2022
How Low-Paid Parents Navigate The Complex Financial Landscape Of Benefits Cliffs And Disincentive Deserts
Kess Ballentine, Sara Goodkind, Jeffrey Shook
BJU International
|
June 7, 2014
Multiparametric magnetic resonance imaging (MRI) and active surveillance for prostate cancer: future directions
Jeffrey K Mullins, H Ballentine Carter
The Journal of Urology
|
December 6, 2014
Re: Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening
H Ballentine Carter, Peter C Albertsen
Journal of the American Pharmacists Association : Japha
|
December 31, 2005
Judging a book by its cover: the predicament with Canadian pharmacy advertisements and American consumers
Amanda J Ballentine, Earlene E Lipowski
European Urology
|
February 21, 2018
Risk Stratification in Active Surveillance: A Dynamic, Ever-Evolving Practice
Jeffrey J Tosoian, H Ballentine Carter
Urology
|
November 22, 2015
Reply
Adam C Reese, H Ballentine Carter
Page
of 46
Search research articles
Search
Showing results (81-90 of 451) with videos related to
Sort By:
Page
of 46
Asian Journal of Andrology
|
April 24, 2012
Helping to address the over treatment of prostate cancer: tools to differentiate lethal and non-lethal phenotype in prostate cancer
Robert H Getzenberg, H Ballentine Carter
Urology
|
December 23, 2014
Reply: To PMID 25440986
Katarzyna J Macura, H Ballentine Carter
Integrative Organismal Biology (Oxford, England)
|
June 17, 2024
The Meioflume: A New System for Observing the Interstitial Behavior of Meiofauna
W M Ballentine, K M Dorgan
The Journal of Urology
|
November 7, 2006
The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate
Danil V Makarov, H Ballentine Carter
Health Affairs (Project Hope)
|
December 5, 2022
How Low-Paid Parents Navigate The Complex Financial Landscape Of Benefits Cliffs And Disincentive Deserts
Kess Ballentine, Sara Goodkind, Jeffrey Shook
BJU International
|
June 7, 2014
Multiparametric magnetic resonance imaging (MRI) and active surveillance for prostate cancer: future directions
Jeffrey K Mullins, H Ballentine Carter
The Journal of Urology
|
December 6, 2014
Re: Relative value of race, family history and prostate specific antigen as indications for early initiation of prostate cancer screening
H Ballentine Carter, Peter C Albertsen
Journal of the American Pharmacists Association : Japha
|
December 31, 2005
Judging a book by its cover: the predicament with Canadian pharmacy advertisements and American consumers
Amanda J Ballentine, Earlene E Lipowski
European Urology
|
February 21, 2018
Risk Stratification in Active Surveillance: A Dynamic, Ever-Evolving Practice
Jeffrey J Tosoian, H Ballentine Carter
Urology
|
November 22, 2015
Reply
Adam C Reese, H Ballentine Carter
Page
of 46